Physician profile
Sandy Park
NPI 1134462039
$2,565.48
in general payments reported to CMS, 2019-2025
13 companies · $594 in 2025
The $594 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2021: $47.58 · 2022: $322 · 2023: $308 · 2024: $1,174 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,049 · Food and Beverage: $1,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,048.88 |
| Food and Beverage | $1,026.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,666.90 | 2019-2025 | Triclip, Mitraclip, Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $140.42 | 2022-2023 | |
| Bridgebio Pharma, INC. | $135.11 | 2025 | Attruby |
| Esperion Therapeutics, INC. | $125.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $123.34 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $113.93 | 2022-2023 | Lifevest |
| Edwards Lifesciences Corporation | $93.53 | 2023 | Sapien 3 Ultra Resilia |
| Pfizer INC. | $57.91 | 2024 | |
| Janssen Pharmaceuticals, INC | $40.86 | 2023-2024 | Xarelto |
| Endotronix, INC. | $26.26 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.11 | 2023 | |
| Alexion Pharmaceuticals, INC. | $20.11 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandy Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.